- Home
- LNTH vs ALKS Comparison
LNTH vs ALKS Comparison
Compare LNTH & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNTH
- ALKS
- Stock Information
- Founded
- LNTH 1956
- ALKS 1987
- Country
- LNTH United States
- ALKS Ireland
- Employees
- LNTH N/A
- ALKS N/A
- Industry
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- LNTH Health Care
- ALKS Health Care
- Exchange
- LNTH Nasdaq
- ALKS Nasdaq
- Market Cap
- LNTH 6.0B
- ALKS 5.7B
- IPO Year
- LNTH 2015
- ALKS 1991
- Fundamental
- Price
- LNTH $78.23
- ALKS $35.32
- Analyst Decision
- LNTH Strong Buy
- ALKS Buy
- Analyst Count
- LNTH 6
- ALKS 12
- Target Price
- LNTH $132.67
- ALKS $37.25
- AVG Volume (30 Days)
- LNTH 832.8K
- ALKS 1.9M
- Earning Date
- LNTH 02-26-2025
- ALKS 02-12-2025
- Dividend Yield
- LNTH N/A
- ALKS N/A
- EPS Growth
- LNTH 304.57
- ALKS 3.47
- EPS
- LNTH 6.02
- ALKS 2.17
- Revenue
- LNTH $1,496,799,000.00
- ALKS $1,557,632,000.00
- Revenue This Year
- LNTH $19.64
- ALKS N/A
- Revenue Next Year
- LNTH $5.16
- ALKS $4.67
- P/E Ratio
- LNTH $12.99
- ALKS $16.28
- Revenue Growth
- LNTH 24.15
- ALKS N/A
- 52 Week Low
- LNTH $56.44
- ALKS $22.90
- 52 Week High
- LNTH $126.89
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- LNTH 31.32
- ALKS 71.72
- Support Level
- LNTH $79.39
- ALKS $31.01
- Resistance Level
- LNTH $84.24
- ALKS $36.45
- Average True Range (ATR)
- LNTH 3.84
- ALKS 1.05
- MACD
- LNTH -0.93
- ALKS 0.32
- Stochastic Oscillator
- LNTH 0.66
- ALKS 81.57
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.